MedTrace Logo

Efficacy of 0.05 % Cyclosporine Ophthalmic Emulsion Compare With Tear in Meibomian Gland Dysfunction

NCT00705510 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2010-11-09

No results posted yet for this study

Summary

To evaluate the efficacy of 0.05% cyclosporine ophthalmic emulsion (Restasis® , Allergan) versus an artificial tears alone in patients with meibomian gland dysfunction that have abnormal tear quality and quantity by subjective symptoms and signs including tear breakup time

Conditions

  • Meibomian Gland Dysfunction

Interventions

DRUG

0.05% cyclosporin eye drop

use the medication twice daily for 3 months

Sponsors & Collaborators

  • Mahidol University

    lead OTHER

Principal Investigators

  • Pinnita Prabhasawat, MD · Department of Ophthalmology, Siriraj H, Mahidol U

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2010-10-31
Completion
2010-10-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00705510 on ClinicalTrials.gov